We create and publish training materials and deal with the research of financial and commodity markets and identification of trading opportunities. We create information content in digital electronic form and its subsequent sale. We are not a stockbroker or broker, we are not financial institutions and we are not a financial intermediary.

20/12/2_WORLD’S FIRST. The British have approved a coronavirus vaccine from Pfizer and BioNTech, vaccination will start next week

The first British people will see a coronavirus vaccine next week. The British government has given the green light to the American pharmaceutical company Pfizer and the German company BioNTech, which can put their vaccines on the market and thus be faster than USA. Health Secretary Matt Hancock immediately announced that fifty hospitals across the country were already waiting for the vaccine.

 

The British Regulatory Agency for Medicines and Medical Products (MHRA) has given its consent to the emergency use of Pfizer-BioNTech, which they say is 95% effective. In record time – just 23 days after the publication of the first data from the last testing phase by Pfizer.

 

Prime Minister Boris Johnson speaks of the medical authority’s approval as a global win and a ray of hope amid the darkness of a new coronavirus that has killed nearly 1.5 million people worldwide, shaken the world economy and thwarted everyday life.

 

The approval of the vaccine for use almost exactly one year after the discovery of the new coronavirus in Wuhan, China, is a triumph for science, Pfizer boss Albert Bourly and his German biotechnology partner BioNTech.

 

The US Food and Drug Administration (FDA) is due to meet on December 10 to discuss whether to recommend an emergency authorization for Pfizer / BioNTech, and the European Medicines Agency (EMA) has said it could provide emergency approval by 29 December.

 

To date, Pfizer’s share price has risen by 3%. It is likely that when the US stock exchange opens, the price will skyrocket.

Source: Reuters.com

Comments

Add comment

Your email address will not be published. Required fields are marked *

Your personal data will only be used for the processing of this comment. Principles of personal data processing